Millennium Management’s Akero Therapeutics AKRO Stock Holding History

Millennium Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,000	Closed	-$907K	–	5987
2025 Q2	$907K	Buy	17,000 +2,000	+13%	+$90.9K	﹤0.01%	4481
2025 Q1	$607K	Buy	+15,000	New	+$636K	﹤0.01%	4694
2023 Q2	–	Sell	-70,000	Closed	-$2.68M	–	6062
2023 Q1	$2.68M	Buy	+70,000	New	+$3.12M	﹤0.01%	3153
2021 Q2	–	Sell	-22,500	Closed	-$653K	–	6466
2021 Q1	$653K	Buy	+22,500	New	+$681K	﹤0.01%	4598

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Millennium Management's AKRO Position: Q4 2025 in Review

Millennium Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 20,197 shares — an estimated $959K sold.

Millennium Management first reported a position in AKRO in Q2 2019 and held it in 21 quarters. The position peaked at $20M in Q1 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Millennium Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Millennium Management sold 20,197 Akero Therapeutics shares in Q4 2025, an estimated $959K.
Millennium Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 21 quarters.
Millennium Management's Akero Therapeutics position peaked at $20M in Q1 2024.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.